Welcome to This Week in Clinical Trials. Every Monday, we share the most notable news in clinical trial results — what was tested, what was found, and what it means for patients. This is our edition for Monday, May 4, 2026.
In today's episode, Novo Nordisk says its new injectable drug Mim8 cut bleeding events by nearly 99 percent in some hemophilia patients, researchers funded by the NIH and the Gates Foundation report a single antibody shot reduced malaria infections by 43 percent in young children in Kenya, and the STAMPEDE research team found that one simple blood test can predict whether a prostate cancer patient is likely to survive eight years. You can find plain english summaries of all the latest completed trials at stellatrials.com/learn.
Novo Nordisk announced that its new drug Mim8 — also called denecimig — dramatically cut bleeds in people with hemophilia type A. The condition affects about 33,000 Americans, mostly men, whose blood is missing a protein it needs to clot. Without treatment, they bleed into joints and muscles for no reason. Over time, those bleeds destroy joints permanently. The standard fix has been IV infusions of a clotting protein, sometimes several times a week.
Mim8 is injected under the skin and does the job that missing protein normally does. In a trial of 281 patients, the headline result was striking: a single shot of Mim8 once a month cut bleeding events by 99 percent compared to treating bleeds only when they happen. No dangerous blood clots appeared, and nobody developed defenses that blocked the drug.
Mim8 is not approved yet. Novo Nordisk plans to file with the FDA. One similar drug — Roche's Hemlibra — has been on the market since 2017. Mim8 would add a once-monthly option Hemlibra doesn't offer.
Now to malaria. Results published in The Lancet show that a single-shot antibody called L9LS can reduce malaria infections in young children in western Kenya. Malaria killed roughly 600,000 people worldwide in 2023, most of them children under five in sub-Saharan Africa.
L9LS is a lab-made antibody that targets the malaria parasite directly. The trial enrolled 912 children — some as young as five months old. Children who received two doses of L9LS, six months apart, were 43 percent less likely to catch malaria over the following year compared to children who got a dummy shot. No serious side effects were linked to the drug.
L9LS is still in early research. This was a Phase 2 trial, so larger studies are needed before approval. The researchers believe a higher dose may be needed for stronger protection in high-transmission areas.
Our last story comes from the STAMPEDE team, running one of the world's longest prostate cancer trials across 126 hospitals in the UK and Switzerland. About 300,000 American men are diagnosed with prostate cancer each year. Doctors have long needed an early signal of who's responding to treatment and who isn't.
Their answer: check the PSA blood test six months in. PSA is a protein that prostate cancer makes. The headline finding from more than 7,000 patients: those whose PSA dropped to nearly undetectable levels by six months had up to 83 percent eight-year survival. That makes the six-month PSA check one of the strongest long-term predictors doctors have ever had.
This isn't a new drug — it's a finding doctors can use today. For doctors weighing whether to push treatment harder, the six-month PSA reading is a clearer answer than they had before.
One quick reminder before we wrap. This show is news, not medical advice. Nothing we cover is meant to replace a conversation with your own doctor about your own care.
That's this week in clinical trials. If any of these conditions affect you or someone you love, head to stellatrials.com — you can search for open trials matched to your situation, and follow the progress of trials as results come in. New episode every Monday. See you next week.